SCHEMBL4908047

SCHEMBL4908047

Cc1nc(O)c(C#N)c(-c2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 5/20 0.42
MAPK14 Q16539 1/20 0.40
ALOX15 P16050 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
DCUN1D1 Q96GG9 2/20 0.38
ADORA2A P29274 4/20 0.38
ADORA1 P30542 4/20 0.38
ADORA2B P29275 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
LDHA P00338 1/20 0.37
LDHB P07195 1/20 0.37
AHR P35869 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4905882 0.85 KMT2A (0.49) KMOMAPK14ALOX15CYP1A2CYP2C9
SCHEMBL4906965 0.82 CA12 (0.39) KMOMAPK14ALOX15DCUN1D1ADORA2A
SCHEMBL4903971 0.82 KMT2A (0.53) KMOMAPK14ALOX15CYP1A2CYP2C9
SCHEMBL4909570 0.79 BRAF (0.39) KMOMAPK14ALOX15DCUN1D1ADORA2A
SCHEMBL4904088 0.79 MAPK14 (0.38) KMOMAPK14ALOX15DCUN1D1ADORA2A
SCHEMBL4908824 0.77 KMO (0.50) KMOMAPK14ALOX15DCUN1D1ADORA2A
SCHEMBL4908950 0.76 MAPK14 (0.36) KMOMAPK14ALOX15DCUN1D1ADORA2A
SCHEMBL4899080 0.75 ALDH1A1 (0.52) ALOX15CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL11366922 0.73 ALOX15 (0.46) KMOMAPK14ALOX15ADORA2AADORA1
SCHEMBL32688256 0.72 IDO1 (0.43) KMOMAPK14CYP1A2CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KMO 3826/4885MAPK14 575/4885ALOX15 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.